Global Antibody Drug Conjugates research

Antibody Drug Conjugates Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Technology (Cleavable Linker, Non-Cleavable Linker), Drugs Type (Adcetris, Kadcyla), Component (Antibody, Cytotoxin, Linker) Players and Region - Global Market Outlook to 2030

Antibody Drug Conjugates Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antibody Drug Conjugates Market Scope?
Antibodies are well recognized in modern treatment of cancer, often in combination with cytotoxic chemotherapy, and exert their therapeutic effect by multiple mechanisms. Though, the activity often seems insufficient and too short lasting. To enhance efficacy, researchers devised the promising strategy of linking antibodies to potent cytotoxic agents to combine specificity with the drugs’ activity. This strategy, known as conjugation, leads to improved activity of both substances, increases drug distribution and reduces harmful exposure of normal tissue. Moreover, conjugation completely alters the pharmacokinetic profile of both components. Antibody drug conjugates permit the targeted delivery of a specific drug dose to the site of interest. It is most commonly employed in oncology, where a high drug dose is required at the tumor site, but not the surrounding tissue.

Influencing Trend:
Advancements in Linking Technologies in Antibody Drug Conjugates

Market Growth Drivers:
Rising Prevalence of Cancer Epidemics, Growing Geriatric Population Base Worldwide and Increasing Demand for Antibody Drug Conjugates and Presence of Strong Product Pipeline

Challenges:
Lack of Experienced Manufacturers

Restraints:
Manufacturing Cost of Antibody-Drug Conjugates Is High

Opportunities:
Rising Demand from Emerging Economies

The Antibody Drug Conjugates market study is being classified, by Application and major geographies with country level break-up.

Key players are implementing various strategies such as mergers & acquisitions, new solution development, joint ventures, partnerships and others. Medical technology and pharmaceutical companies are setting standards by providing new antibody drug conjugates with the help of various technological advancements. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Antibody Drug Conjugates market throughout the predicted period.

F. Hoffman-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Pfizer, Inc. (United States), Sanofi S.A. (France), Seattle Genetics Inc. (United States), Genentech Inc. (United States), Immunogen Inc. (United States), Immunomedics, Inc. (United States) and Bayer Healthcare Pharmaceuticals (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Agensys, Inc. (United States), Progenics Pharmaceuticals Inc. (United States), Concortis Biotherapeutics (United States) and Celldex Therapeutics Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Antibody Drug Conjugates market by Type, Application and Region.

On the basis of geography, the market of Antibody Drug Conjugates has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Key Target Audience
Antibody Drug Conjugates Providers, Suppliers of Antibody Drug Conjugates Components, Healthcare Industry, Pharmaceuticals, Governmental Bodies and Research Firms

Antibody Drug Conjugates Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Antibody Drug Conjugates Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Antibody Drug Conjugates industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
By Technology
  • Cleavable Linker
  • Non-Cleavable Linker

By Drugs Type
  • Adcetris
  • Kadcyla

By Component
  • Antibody
  • Cytotoxin
  • Linker

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer Epidemics
      • 3.2.2. Growing Geriatric Population Base Worldwide
      • 3.2.3. Increasing Demand for Antibody Drug Conjugates and Presence of Strong Product Pipeline
    • 3.3. Market Challenges
      • 3.3.1. Lack of Experienced Manufacturers
    • 3.4. Market Trends
      • 3.4.1. Advancements in Linking Technologies in Antibody Drug Conjugates
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Drug Conjugates, by Application, Technology, Drugs Type, Component and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Antibody Drug Conjugates (Value)
      • 5.2.1. Global Antibody Drug Conjugates by: Application (Value)
        • 5.2.1.1. Blood Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Ovarian Cancer
        • 5.2.1.4. Lung Cancer
        • 5.2.1.5. Brain Tumor
      • 5.2.2. Global Antibody Drug Conjugates by: Technology (Value)
        • 5.2.2.1. Cleavable Linker
        • 5.2.2.2. Non-Cleavable Linker
      • 5.2.3. Global Antibody Drug Conjugates by: Drugs Type (Value)
        • 5.2.3.1. Adcetris
        • 5.2.3.2. Kadcyla
      • 5.2.4. Global Antibody Drug Conjugates by: Component (Value)
        • 5.2.4.1. Antibody
        • 5.2.4.2. Cytotoxin
        • 5.2.4.3. Linker
      • 5.2.5. Global Antibody Drug Conjugates Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antibody Drug Conjugates (Price)
  • 6. Antibody Drug Conjugates: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Seattle Genetics Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genentech Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Immunogen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Immunomedics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer Healthcare Pharmaceuticals (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibody Drug Conjugates Sale, by Application, Technology, Drugs Type, Component and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Antibody Drug Conjugates (Value)
      • 7.2.1. Global Antibody Drug Conjugates by: Application (Value)
        • 7.2.1.1. Blood Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Ovarian Cancer
        • 7.2.1.4. Lung Cancer
        • 7.2.1.5. Brain Tumor
      • 7.2.2. Global Antibody Drug Conjugates by: Technology (Value)
        • 7.2.2.1. Cleavable Linker
        • 7.2.2.2. Non-Cleavable Linker
      • 7.2.3. Global Antibody Drug Conjugates by: Drugs Type (Value)
        • 7.2.3.1. Adcetris
        • 7.2.3.2. Kadcyla
      • 7.2.4. Global Antibody Drug Conjugates by: Component (Value)
        • 7.2.4.1. Antibody
        • 7.2.4.2. Cytotoxin
        • 7.2.4.3. Linker
      • 7.2.5. Global Antibody Drug Conjugates Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antibody Drug Conjugates (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Drug Conjugates: by Application(USD Million)
  • Table 2. Antibody Drug Conjugates Blood Cancer , by Region USD Million (2018-2023)
  • Table 3. Antibody Drug Conjugates Breast Cancer , by Region USD Million (2018-2023)
  • Table 4. Antibody Drug Conjugates Ovarian Cancer , by Region USD Million (2018-2023)
  • Table 5. Antibody Drug Conjugates Lung Cancer , by Region USD Million (2018-2023)
  • Table 6. Antibody Drug Conjugates Brain Tumor , by Region USD Million (2018-2023)
  • Table 7. Antibody Drug Conjugates: by Technology(USD Million)
  • Table 8. Antibody Drug Conjugates Cleavable Linker , by Region USD Million (2018-2023)
  • Table 9. Antibody Drug Conjugates Non-Cleavable Linker , by Region USD Million (2018-2023)
  • Table 10. Antibody Drug Conjugates: by Drugs Type(USD Million)
  • Table 11. Antibody Drug Conjugates Adcetris , by Region USD Million (2018-2023)
  • Table 12. Antibody Drug Conjugates Kadcyla , by Region USD Million (2018-2023)
  • Table 13. Antibody Drug Conjugates: by Component(USD Million)
  • Table 14. Antibody Drug Conjugates Antibody , by Region USD Million (2018-2023)
  • Table 15. Antibody Drug Conjugates Cytotoxin , by Region USD Million (2018-2023)
  • Table 16. Antibody Drug Conjugates Linker , by Region USD Million (2018-2023)
  • Table 17. South America Antibody Drug Conjugates, by Country USD Million (2018-2023)
  • Table 18. South America Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 19. South America Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 20. South America Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 21. South America Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 22. Brazil Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 23. Brazil Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 24. Brazil Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 25. Brazil Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 26. Argentina Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 27. Argentina Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 28. Argentina Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 29. Argentina Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 30. Rest of South America Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 32. Rest of South America Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 33. Rest of South America Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 34. Asia Pacific Antibody Drug Conjugates, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 37. Asia Pacific Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 38. Asia Pacific Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 39. China Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 40. China Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 41. China Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 42. China Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 43. Japan Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 44. Japan Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 45. Japan Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 46. Japan Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 47. India Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 48. India Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 49. India Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 50. India Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 51. South Korea Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 52. South Korea Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 53. South Korea Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 54. South Korea Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 55. Taiwan Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 56. Taiwan Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 57. Taiwan Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 58. Taiwan Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 59. Australia Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 60. Australia Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 61. Australia Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 62. Australia Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 67. Europe Antibody Drug Conjugates, by Country USD Million (2018-2023)
  • Table 68. Europe Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 69. Europe Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 70. Europe Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 71. Europe Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 72. Germany Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 73. Germany Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 74. Germany Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 75. Germany Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 76. France Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 77. France Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 78. France Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 79. France Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 80. Italy Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 81. Italy Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 82. Italy Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 83. Italy Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 84. United Kingdom Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 86. United Kingdom Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 87. United Kingdom Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 88. Netherlands Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 89. Netherlands Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 90. Netherlands Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 91. Netherlands Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 92. Rest of Europe Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 94. Rest of Europe Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 95. Rest of Europe Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 96. MEA Antibody Drug Conjugates, by Country USD Million (2018-2023)
  • Table 97. MEA Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 98. MEA Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 99. MEA Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 100. MEA Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 101. Middle East Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 102. Middle East Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 103. Middle East Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 104. Middle East Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 105. Africa Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 106. Africa Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 107. Africa Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 108. Africa Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 109. North America Antibody Drug Conjugates, by Country USD Million (2018-2023)
  • Table 110. North America Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 111. North America Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 112. North America Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 113. North America Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 114. United States Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 115. United States Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 116. United States Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 117. United States Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 118. Canada Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 119. Canada Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 120. Canada Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 121. Canada Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 122. Mexico Antibody Drug Conjugates, by Application USD Million (2018-2023)
  • Table 123. Mexico Antibody Drug Conjugates, by Technology USD Million (2018-2023)
  • Table 124. Mexico Antibody Drug Conjugates, by Drugs Type USD Million (2018-2023)
  • Table 125. Mexico Antibody Drug Conjugates, by Component USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Antibody Drug Conjugates: by Application(USD Million)
  • Table 137. Antibody Drug Conjugates Blood Cancer , by Region USD Million (2025-2030)
  • Table 138. Antibody Drug Conjugates Breast Cancer , by Region USD Million (2025-2030)
  • Table 139. Antibody Drug Conjugates Ovarian Cancer , by Region USD Million (2025-2030)
  • Table 140. Antibody Drug Conjugates Lung Cancer , by Region USD Million (2025-2030)
  • Table 141. Antibody Drug Conjugates Brain Tumor , by Region USD Million (2025-2030)
  • Table 142. Antibody Drug Conjugates: by Technology(USD Million)
  • Table 143. Antibody Drug Conjugates Cleavable Linker , by Region USD Million (2025-2030)
  • Table 144. Antibody Drug Conjugates Non-Cleavable Linker , by Region USD Million (2025-2030)
  • Table 145. Antibody Drug Conjugates: by Drugs Type(USD Million)
  • Table 146. Antibody Drug Conjugates Adcetris , by Region USD Million (2025-2030)
  • Table 147. Antibody Drug Conjugates Kadcyla , by Region USD Million (2025-2030)
  • Table 148. Antibody Drug Conjugates: by Component(USD Million)
  • Table 149. Antibody Drug Conjugates Antibody , by Region USD Million (2025-2030)
  • Table 150. Antibody Drug Conjugates Cytotoxin , by Region USD Million (2025-2030)
  • Table 151. Antibody Drug Conjugates Linker , by Region USD Million (2025-2030)
  • Table 152. South America Antibody Drug Conjugates, by Country USD Million (2025-2030)
  • Table 153. South America Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 154. South America Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 155. South America Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 156. South America Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 157. Brazil Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 158. Brazil Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 159. Brazil Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 160. Brazil Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 161. Argentina Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 162. Argentina Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 163. Argentina Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 164. Argentina Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 165. Rest of South America Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 166. Rest of South America Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 167. Rest of South America Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 168. Rest of South America Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 169. Asia Pacific Antibody Drug Conjugates, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 171. Asia Pacific Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 172. Asia Pacific Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 173. Asia Pacific Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 174. China Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 175. China Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 176. China Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 177. China Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 178. Japan Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 179. Japan Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 180. Japan Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 181. Japan Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 182. India Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 183. India Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 184. India Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 185. India Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 186. South Korea Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 187. South Korea Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 188. South Korea Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 189. South Korea Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 190. Taiwan Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 191. Taiwan Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 192. Taiwan Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 193. Taiwan Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 194. Australia Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 195. Australia Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 196. Australia Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 197. Australia Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 202. Europe Antibody Drug Conjugates, by Country USD Million (2025-2030)
  • Table 203. Europe Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 204. Europe Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 205. Europe Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 206. Europe Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 207. Germany Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 208. Germany Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 209. Germany Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 210. Germany Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 211. France Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 212. France Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 213. France Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 214. France Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 215. Italy Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 216. Italy Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 217. Italy Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 218. Italy Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 219. United Kingdom Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 220. United Kingdom Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 221. United Kingdom Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 222. United Kingdom Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 223. Netherlands Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 224. Netherlands Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 225. Netherlands Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 226. Netherlands Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 227. Rest of Europe Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 228. Rest of Europe Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 229. Rest of Europe Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 230. Rest of Europe Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 231. MEA Antibody Drug Conjugates, by Country USD Million (2025-2030)
  • Table 232. MEA Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 233. MEA Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 234. MEA Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 235. MEA Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 236. Middle East Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 237. Middle East Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 238. Middle East Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 239. Middle East Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 240. Africa Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 241. Africa Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 242. Africa Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 243. Africa Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 244. North America Antibody Drug Conjugates, by Country USD Million (2025-2030)
  • Table 245. North America Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 246. North America Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 247. North America Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 248. North America Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 249. United States Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 250. United States Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 251. United States Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 252. United States Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 253. Canada Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 254. Canada Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 255. Canada Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 256. Canada Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 257. Mexico Antibody Drug Conjugates, by Application USD Million (2025-2030)
  • Table 258. Mexico Antibody Drug Conjugates, by Technology USD Million (2025-2030)
  • Table 259. Mexico Antibody Drug Conjugates, by Drugs Type USD Million (2025-2030)
  • Table 260. Mexico Antibody Drug Conjugates, by Component USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Drug Conjugates: by Application USD Million (2018-2023)
  • Figure 5. Global Antibody Drug Conjugates: by Technology USD Million (2018-2023)
  • Figure 6. Global Antibody Drug Conjugates: by Drugs Type USD Million (2018-2023)
  • Figure 7. Global Antibody Drug Conjugates: by Component USD Million (2018-2023)
  • Figure 8. South America Antibody Drug Conjugates Share (%), by Country
  • Figure 9. Asia Pacific Antibody Drug Conjugates Share (%), by Country
  • Figure 10. Europe Antibody Drug Conjugates Share (%), by Country
  • Figure 11. MEA Antibody Drug Conjugates Share (%), by Country
  • Figure 12. North America Antibody Drug Conjugates Share (%), by Country
  • Figure 13. Global Antibody Drug Conjugates share by Players 2023 (%)
  • Figure 14. Global Antibody Drug Conjugates share by Players (Top 3) 2023(%)
  • Figure 15. Global Antibody Drug Conjugates share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. F. Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. F. Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 23. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 27. Seattle Genetics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Seattle Genetics Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Genentech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Genentech Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Immunogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Immunogen Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Immunomedics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Immunomedics, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Bayer Healthcare Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer Healthcare Pharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 37. Global Antibody Drug Conjugates: by Application USD Million (2025-2030)
  • Figure 38. Global Antibody Drug Conjugates: by Technology USD Million (2025-2030)
  • Figure 39. Global Antibody Drug Conjugates: by Drugs Type USD Million (2025-2030)
  • Figure 40. Global Antibody Drug Conjugates: by Component USD Million (2025-2030)
  • Figure 41. South America Antibody Drug Conjugates Share (%), by Country
  • Figure 42. Asia Pacific Antibody Drug Conjugates Share (%), by Country
  • Figure 43. Europe Antibody Drug Conjugates Share (%), by Country
  • Figure 44. MEA Antibody Drug Conjugates Share (%), by Country
  • Figure 45. North America Antibody Drug Conjugates Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer, Inc. (United States)
  • Sanofi S.A. (France)
  • Seattle Genetics Inc. (United States)
  • Genentech Inc. (United States)
  • Immunogen Inc. (United States)
  • Immunomedics, Inc. (United States)
  • Bayer Healthcare Pharmaceuticals (Germany)
Additional players considered in the study are as follows:
Agensys, Inc. (United States) , Progenics Pharmaceuticals Inc. (United States) , Concortis Biotherapeutics (United States) , Celldex Therapeutics Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 231 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Drug Conjugates research Quantitative research analysis
Global Antibody Drug Conjugates research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Antibody Drug Conjugates market are F. Hoffman-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Pfizer, Inc. (United States), Sanofi S.A. (France), Seattle Genetics Inc. (United States), Genentech Inc. (United States), Immunogen Inc. (United States), Immunomedics, Inc. (United States) and Bayer Healthcare Pharmaceuticals (Germany).
In this highly competitive & fast evolving Antibody Drug Conjugates industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor are the potential customers of Antibody Drug Conjugates industry.

Know More About Global Antibody Drug Conjugates research Report?

Have a Query? Click Here

Other Related Reports

Swine Diseases Treatment Comprehensive Study by Type (Drugs, Vaccines), Application (Private Veterinary Hospitals, Private Veterinary Pharmacies, Government Veterinary Clinics, Others), Drugs (Anti-I...
$ 3750
Patient Lateral Transfer Comprehensive Study by Type (Air-assisted Lateral Transfer Mattress (Regular Mattress, Split-leg Mattress, Half Mattress), Air-assisted Lateral Transfer Mattress (Reusable Ai...
$ 3750
Clinical Workflow Solution Comprehensive Study by Type (Data Integration, EMR Integration, Nurse Call Systems, Unified Communications, Care Solutions, Patient Flow Management Enterprise Solutions), A...
$ 3650
Renal Function Test Comprehensive Study by Type (Disposables, Reagents, Dipsticks, Other Products), Application (Hospitals, Clinics, Diagnostic Laboratories, Others), Parameters (Serum Urea (15-45 mg...
$ 3750
Chronic Diseases Management Comprehensive Study by Application (Ambulatory Care Centers, Hospitals and Physician Groups, Diagnostic Centers, Home Healthcare Agencies and Nursing Homes, Others), Disea...
$ 3450
Salmonella Testing Comprehensive Study by Type (Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, Differential Light Scattering), Application (Hospitals, Public Health Labs, Physician Offic...
$ 3350